0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-509.76%PremiumSep 20, 2024Expiry Date6.27Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.20Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Enlivex Therapeutics Stock Discussion
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Therapeutics (Nasdaq: ENLV) has received regulatory approval from the Israeli Ministry of Health to initiate a Phase I/II trial of Allocetra™ for thumb osteoarthritis. This is the first study of Allocetra™ in thumb osteoarthritis, following previous studies in knee osteoarthritis. The ...
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
NEWS
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Which is more important when picking a trade:
Earning or FDA outcome
Acquisition or Market sentiment
Happy to learn from friends here.
$Enlivex Therapeutics (ENLV.US)$
$Akebia Therapeutics (AKBA.US)$
$Rekor Systems (REKR.US)$
$OncoCyte (OCX.US)$
NEWS
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
NEWS
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Enlivex Therapeutics (ENLV) announces positive results from Phase II study of Allocetra™ in sepsis patients, showing significant reductions in SOFA scores and mortality rates. The study indicates a potential market opportunity for Allocetra™ in high-risk sepsis patients originating from urinary tract infections.
Positive indication of effect and safety result...
Must Delete Now 😡🔥👎
No comment yet